The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| TVRD | -58.21% | -99.12% | -61.21% | -75% |
| S&P | +18.54% | +92.9% | +14.04% | +28% |
CARA Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs). Its portfolio includes opioid-based products, anesthetic-based drugs, and analgesics that targets to alleviate itch and pain. The company was founded by Derek T. Chalmers, Michael E. Lewis, and Frederique Menzaghi on July 2, 2004 and is headquartered in Stamford, CT.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | -100.0% |
| Gross Profit | -$0.05M | -105.1% |
| Gross Margin | 97.14% | 0.0% |
| Market Cap | $218.39M | 1448.4% |
| Market Cap / Employee | $19.85M | 0.0% |
| Employees | 11 | 0.0% |
| Net Income | $4.17M | 120.8% |
| EBITDA | -$8.82M | 45.3% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $20.65M | -58.1% |
| Accounts Receivable | $1.23M | -28.5% |
| Inventory | 0 | -100.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.15M | -99.7% |
| Short Term Debt | $0.11M | -35.1% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -35.95% | 71.4% |
| Return On Invested Capital | -77.02% | -24.4% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$8.87M | 29.9% |
| Operating Free Cash Flow | -$8.87M | 28.7% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 23.89 | -6.09 | -2.87 | -4.41 | -1031.04% |
| Price to Sales | 1.94 | 3.92 | 3.06 | 29.98 | 2234.78% |
| Price to Tangible Book Value | 52.43 | 118.69 | -15.14 | -4.41 | -125.86% |
| Enterprise Value to EBITDA | -2.79 | -5.75 | -14.58 | -17.74 | 6037.21% |
| Return on Equity | -221.3% | -270.0% | -414.9% | -93.9% | -49.08% |
| Total Debt | $44.00M | $44.45M | $45.82M | $0.25M | -99.46% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
